2025-12-31 - Analysis Report
Okay, here's a breakdown and analysis of UnitedHealth Group (UNH) based on the data you provided.

**1) Return Rate Comparison (UNH vs. S&P 500 (VOO))**

*   **UNH Overview:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services.

*   **Cumulative Returns:**
    *   UNH: -17.22%
    *   VOO (S&P 500): 102.21%

*   **Divergence:**
    *   Current: -120.5
    *   Range: -130.7 (min) to 36.3 (max)
    *   Relative Divergence: 6.1 (meaning the current divergence is near the bottom of its historical range)

*   **Analysis:** UNH has significantly underperformed the S&P 500 over the specified period, resulting in a large negative divergence. The relative divergence suggests that this underperformance is near the worst it has been historically (within the analyzed period).

*   **Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD  | Alpha  | Beta | Cap(B) |
|------------|--------|------|--------|------|--------|
| 2015-2017  | 58.0%  | 66.4% | 30.0%  | 0.1  | 199.7  |
| 2016-2018  | 41.0%  | 70.4% | 26.0%  | 0.1  | 225.7  |
| 2017-2019  | 36.0%  | 73.8% | 14.0%  | 0.2  | 266.3  |
| 2018-2020  | -43.0% | 81.2% | -67.0% | 0.5  | 317.7  |
| 2019-2021  | 16.0%  | 81.2% | -30.0% | 1.5  | 454.9  |
| 2020-2022  | -1.0%  | 81.2% | 0.0%   | 1.5  | 480.3  |
| 2021-2023  | 24.0%  | 80.8% | 23.0%  | 0.4  | 476.9  |
| 2022-2024  | -27.0% | 78.8% | -47.0% | 0.3  | 458.2  |
| 2023-2025  | -60.0% | 79.8% | -126.0%| 1.2  | 300.9  |

*   **Analysis of Alpha/Beta:**
    *   **Alpha:** Alpha has been predominantly negative in recent periods (especially 2018-2020, 2019-2021, 2022-2024, and 2023-2025), indicating UNH has underperformed its benchmark (likely the S&P 500). The most recent period (2023-2025) shows a significantly negative alpha of -126.0%.
    *   **Beta:** Beta has increased and fluctuated more recently, suggesting UNH's volatility relative to the market has increased. Higher beta values (especially 1.5 in 2019-2021 and 2020-2022) suggest the stock became more sensitive to market movements during those periods.
    *   **CAGR:** CAGR has been negative in several recent periods (2018-2020, 2020-2022, 2022-2024, and 2023-2025), consistent with the underperformance.
    *   **MDD:** Maximum Drawdown is high throughout the period, indicating significant peak-to-trough declines.
    *   **Cap(B):** Market capitalization decreased a lot in the latest period.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 332.16
*   **Previous Close:** 328.94
*   **Change:** 0.98
*   **5-day SMA:** 329.06
*   **20-day SMA:** 331.05
*   **60-day SMA:** 337.99

*   **Analysis:** The current price is slightly above the 5-day and 20-day SMAs but still below the 60-day SMA. This suggests a short-term upward trend, but the price still faces resistance at the 60-day level. The positive change from the previous close indicates some upward momentum.

**3) RSI, PPO, and Divergence Analysis**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 58.84 (Neutral)
*   **PPO:** 0.06 (Neutral)
*   **Hybrid Signal:** "cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21"
*   **Recent (20 days) relative divergence change:** -1.9 (Negative - Short-term decline)
*   **Expected Return (%):** -328.2% (Negative expected excess return)

*   **Analysis:**
    *   **MRI:** The Market Risk Indicator suggests a high investment recommendation, contradicting other negative signals. This should be viewed with caution.
    *   **RSI:** An RSI of 58.84 is neutral, not indicating overbought or oversold conditions.
    *   **PPO:** A PPO of 0.06 is also relatively neutral, suggesting the stock price is near its average.
    *   **Hybrid Signal:** The hybrid signal suggests buying a significant portion of available cash, framing this as a relatively safe investment, with dividend yield.
    *   **Divergence Change:** The recent decrease in relative divergence suggests short-term downward pressure, further supporting the underperformance narrative.
    *   **Expected Return:** The extremely negative expected return is a significant warning sign, indicating that long-term investment from this point is projected to significantly underperform the S&P 500.
    *   **Price change impact:** With a change of 0.98 compared to the previousClose of 328.94, this could indicate small price fluctuation issue, although the market price is rebounding.

**4) Recent News & Significant Events:**

*   **Forbes:** 3 Risks That Can Make UnitedHealth Stock Unattractive
*   **Zacks:** UNH vs. ELV: Which Managed Care Stock Has the Edge Today? (Implies potential concerns or alternatives)
*   **ts2.tech:** UnitedHealthcare delays remote monitoring policy (Potential regulatory or operational impact)
*   **Seeking Alpha:** UnitedHealth: Undervalued Blue-Chip Stock With Multiple Levers To Pull & Ways To Win (Contrasting viewpoint)
*   **Meyka:** Minnesota Fraud Probe Flags Medicaid Risk
*   **Trefis:** Can UnitedHealth Stock Withstand These Pressures?

*   **Analysis:** Recent news presents a mixed picture. Some articles highlight risks, fraud probes, and delays that could negatively affect the stock. Others suggest the stock is undervalued and has potential for growth. The differing viewpoints highlight the uncertainty surrounding UNH.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (Buy)
*   **Opinions:** 25
*   **Target Price:** 392.24 (Avg) / 440.00 (High) / 280.00 (Low)

*   **Analysis:** Despite the recent negative performance, analysts generally have a "Buy" rating on UNH with a target price significantly above the current price. However, the wide range in target prices (280.00 to 440.00) suggests uncertainty.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-10-28 | 2.59 | 113.16 B$    |
| 2025-08-11 | 3.76 | 111.62 B$    |
| 2025-05-07 | 6.9  | 109.58 B$    |
| 2024-11-04 | 6.56 | 100.82 B$    |
| 2025-10-28 | 6.56 | 100.82 B$    |

*   **Analysis:** Revenue has been generally increasing over the past few quarters. However, the most recent EPS (2.59) is significantly lower than previous quarters. This sharp drop in EPS is concerning. There is a duplicated data (2025-10-28)

**6) Financial Information:**

*   **Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $113.16B  | 18.24%        |
| 2025-06-30   | $111.62B  | 17.93%        |
| 2025-03-31   | $109.58B  | 21.70%        |
| 2024-12-31   | $100.81B  | 21.14%        |
| 2024-09-30   | $100.82B  | 22.84%        |

*   **Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $95.79B   | 2.45%   |
| 2025-06-30   | $94.72B   | 3.60%   |
| 2025-03-31   | $95.04B   | 6.62%   |
| 2024-12-31   | $92.66B   | 5.98%   |
| 2024-09-30   | $94.53B   | 6.41%   |

*   **Analysis:**
    *   **Revenue:** Revenue has been growing steadily.
    *   **Profit Margin:** Profit margins have fluctuated but generally trended downward in recent quarters, which could explain the drop in EPS.
    *   **Equity:** Equity has remained relatively stable.
    *   **ROE:** Return on Equity has significantly decreased in recent quarters, also indicating declining profitability.

**7) Comprehensive Analysis (Summary)**

Overall, the analysis paints a concerning picture of UNH:

*   **Underperformance:** UNH has significantly underperformed the S&P 500.
*   **Negative Alpha:**  The company has consistently generated negative alpha, indicating underperformance relative to its benchmark.
*   **Declining Profitability:** Recent earnings (EPS), profit margins, and ROE have declined.
*   **Mixed Signals:** While analysts have a generally positive outlook, technical indicators and news headlines suggest caution. The Market Risk Indicator contradicts other bearish signals.
*   **Fraud Probe/Risks:** News about fraud probes and other risks create uncertainty.
*   **Negative Future Outlook:** Very negative Expected return should be cautious.

**Recommendation:**

Based on this analysis, I would advise caution before investing in UNH. The significant underperformance, declining profitability, and negative future outlook are concerning. While analysts are generally positive, the mixed signals from technical indicators, news, and recent earnings suggest that there may be significant challenges facing the company. The conflicting "High Investment Recommended" MRI rating should be questioned. Further investigation into the reasons for the declining EPS, profit margins, and the impact of the identified risks would be warranted before making an investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.